Advancing drug discovery through #AI, #OpenScience, and #Collaboration between academia, industry, and non-profits to create accessible treatments for all. More about us at conscience.ca
Conscience
Loading...
We're pleased to share Conscience's first Annual Report! In 2025, we made significant progress in advancing open science drug discovery by funding projects, expanding the CACHE Challenges, providing advisory services, and launching BEACON. Read the report here: conscience.ca/reports/
CACHE4 results are out! All previously known CBLCB ligands shared the same scaffold. Congrats to Keunwan Park who successfully designed a chemically novel series, to the experimental team at @thesgc.bsky.social and thanks to @conscience-network.bsky.social for greasing the wheels! bit.ly/4mYNe3r
Are you leading an #OpenScience initiative advancing the field of #neuroscience? Don’t miss this opportunity to be recognized for your contributions. Submit your application for the Neuro-Irv and Helga Cooper Foundation Open Science Prizes today!
👉Apply now! -link in comments
#neurology #datasharing
Conscience
The deadline to apply for CACHE Challenge #7 has been extended to October 10! This challenge focuses on discovering selective inhibitors of PGK2, a promising target for non-hormonal contraception. 🇨🇦 Canadian participants can access reimbursement funds! Learn more here: conscience.ca/event/cache7/
Our CEO, Peng Fu, and Chief Policy and Partnerships Officer @richardgold.bsky.social are in Paris this week for the OECD Workshop on Open Science and Innovation Partnerships. We’re excited to hear how the discussions unfold and to learn from the insights and lessons emerging from the workshop!
On Oct 16, @dylan-re.bsky.social and @richardgold.bsky.social will be hosting an infosession on our Open Science Advisory Services program, which provides funding to help you hire the expertise you need for your open science project. Learn more and register here:
conscience.ca/event/open-s...
Drug discovery is becoming slower and more expensive, but collaboration, and open science can change that. In this new op-ed, Conscience CEO Peng Fu and @estrid-j.bsky.social argue that the real breakthroughs will come from rethinking how science gets done.
đź”— www.ddw-online.com/from-risk-to...
This new op-ed by @richardgold.bsky.social describes how sequencing #OpenScience before #IntellectualProperty companies can accelerate innovation while reducing cost and risk. It features our CACHE Challenges as an example of an open science initiative that can greatly benefit participating SMEs!
In this op-ed, @richardgold.bsky.social and co-authors argue that Canada must take advantage of instability in U.S. research funding by rethinking how universities support innovation - shifting away from patents toward long-term partnerships and open science. www.nationalobserver.com/2025/07/11/o...
⏳Just a few days left to apply to join CACHE Challenge #7: Finding selective inhibitors of PGK2 for non-hormonal contraception. Don't miss this chance to test your models with high-quality experimental data!
Deadline: September 15, 2025
Learn more and apply here: conscience.ca/event/cache7/
Conscience Annual Reports 2025 Conscience’s first Annual Report highlights our progress in advancing open science drug discovery, from early-stage research through to clinical translation, while stren...
Great morning representing #TRIDENT & @westernu.ca at the @oecd-ocde.bsky.social Open Science & Innovation Partnerships Workshop: bringing global leaders together to turn research into real-world impact. Big thanks to #NFRF + @conscience-network.bsky.social for making this possible!🤝🌍
We’re pleased to launch the seventh CACHE Challenge, which is now accepting applications. The deadline to apply is September 15, 2025. The CACHE Challenges, made possible by the Government of Canada’s...
conscience.ca
Canadian universities have an excellent track record of creating and preserving knowledge, but a poor one for helping innovators to develop products and services.
Simplistic models of #IntellectualProperty get in the way of building a biopharmaceutical company. Here I discuss how going #OpenScience can lead to proprietary rights later on: www.lifescienceleader.com/doc/open-sci... @conscience-network.bsky.social @tridentpct.bsky.social
E. Richard Gold
By sharing early-stage tools and data openly, life sciences companies can minimize duplication and de-risk R&D without risking exclusive rights over valuable assets, writes Richard Gold.
